Current Report Filing (8-k)
March 19 2021 - 4:30PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
March 18, 2021
INOTIV, INC.
(Exact name of registrant as specified in
its charter)
Indiana
|
|
0-23357
|
|
35-1345024
|
(State or other
jurisdiction of
incorporation or
organization)
|
|
(Commission File
Number)
|
|
(I.R.S. Employer
Identification No.)
|
2701 Kent Avenue
West Lafayette, Indiana
|
|
47906-1382
|
(Address of principal executive offices)
|
|
(Zip Code)
|
Registrant’s telephone number, including
area code: (765) 463-4527
Bioanalytical
Systems, Inc.
(Former name or former address, if changed
since last report)
Check the appropriate box below if the Form 8-K filing
is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
|
o
|
Written communications pursuant to Rule 425 under
the Securities Act (17 CFR 230.425)
|
|
o
|
Soliciting material pursuant to Rule 14a-12 under
the Exchange Act (17CFR240.14a-12)
|
|
o
|
Pre-commencement communications pursuant to Rule 14d-2(b) under
the Exchange Act (17CFR240.14d-2(b))
|
|
o
|
Pre-commencement communications pursuant to Rule 13e-4(c) under
the Exchange Act (17CFR240.13e-4(c))
|
Securities registered pursuant to Section
12(b) of the Act:
Title of each class
|
Trading Symbols
|
Name of exchange on which registered
|
Common Shares
|
BASi
|
NASDAQ Capital Market
|
Indicate by check mark whether the registrant is an emerging
growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities
Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company o
If an emerging growth company, indicate by check mark if the
registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards
provided pursuant to Section 13(a) of the Exchange Act. o
Item 5.03 Amendments to Articles of Incorporation or Bylaws;
Change in Fiscal Year
On March 18, 2021,
Inotiv, Inc. (the “Company”) filed Articles of Amendment to its Second Amended and Restated Articles of Incorporation,
as amended (the “Articles”), reflecting its corporate name change from Bioanalytical Systems, Inc. to Inotiv, Inc.,
effective on March 18, 2021. In addition, on March 18, 2021, the Company revised its Second Amended and Restated Bylaws, as amended
(the “Bylaws”), to reflect its corporate name change.
This summary is
qualified in its entirety by reference to the Articles and Bylaws, copies of which are attached hereto as Exhibit 3.1 and
Exhibit 3.2, respectively, and are incorporated here by reference.
Item 5.07 Submission of Matters to a Vote of Security Holders
On March 18, 2021, the Company held its
annual meeting of shareholders. A total of 8,378,513 shares of the Company’s common stock outstanding and entitled to vote
were present at the meeting in person or by proxy. The following is a summary of matters voted on at the meeting:
|
a.
|
Two Class III members of the Board of Directors were elected to serve a three-year term ending in 2024 with the following votes
cast:
|
Nominee
|
|
For
|
|
Withheld
|
|
Broker Non-Vote
|
Gregory C. Davis, Ph.D.
|
|
5,488,294
|
|
697,021
|
|
2,193,198
|
John E. Sagartz, DVM, PhD, DACVP
|
|
5,523,647
|
|
661,668
|
|
2,193,198
|
|
b.
|
The appointment of RSM US LLP as our independent registered public accountants for fiscal 2021
was ratified by the following shareholder vote:
|
Vote Type
|
|
Voted
|
For
|
|
7,715,194
|
Against
|
|
3,169
|
Abstain
|
|
660,150
|
|
c.
|
The proposal to approve the filing of Articles of Amendment to the Company’s Second Amended
and Restated Articles of Incorporation, as amended, in order to change our corporate name to Inotiv, Inc., passed with the following
votes cast:
|
Vote Type
|
|
Voted
|
For
|
|
8,224,039
|
Against
|
|
126,578
|
Abstain
|
|
27,896
|
Item 7.01 Regulation FD Disclosure.
On March 19, 2021,
the Company issued the attached press release regarding the Company’s corporate name change to Inotiv, Inc. The information
furnished under Item 7.01 of this Current Report on Form 8-K and in Exhibit 99.1 attached hereto shall not be deemed “filed”
for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or incorporated
by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set
forth by specific reference in such a filing.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits
Exhibit No.
|
|
Description
|
3.1
|
|
Second Amended and Restated Articles of Incorporation of Inotiv, Inc. (formerly known as Bioanalytical Systems, Inc.), as amended through March 18, 2021
|
3.2
|
|
Second Amended and Restated Bylaws of Inotiv, Inc. (formerly known as Bioanalytical Systems, Inc.), as amended through March 18, 2021
|
99.1
|
|
Press Release, dated March 19, 2021.
|
SIGNATURES
Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
Inotiv, Inc.
|
|
|
|
|
Date: March 19, 2021
|
By:
|
/s/ Beth A. Taylor
|
|
Beth A. Taylor
|
|
|
Chief Financial Officer, Vice President – Finance
|
|
|
|
|
Bioanalytical Systems (NASDAQ:BASI)
Historical Stock Chart
From Mar 2024 to Apr 2024
Bioanalytical Systems (NASDAQ:BASI)
Historical Stock Chart
From Apr 2023 to Apr 2024